Replies to post #5994 on ANI Pharmaceuticals (ANIP)

[Just the facts maam]

Jadite, I am not going anywhere until Libigel is realized. If they intended not to do anything with it, the CV risk reduction results would have been made public, so that other researchers could use the information. Dr Sullivan, BPAX Chairman of the Board, would have pushed for that.

I am encouraged that ABBVIE has not used the Priority Review Voucher on another product, yet. Therefore, it is still in play if they make a move on Libigel.

If, as many of us suspect, ABBVIE and Dr Snabes are interested in Libigel. The uncertainty regarding competition with Humira (potential loss of revenue) from both biosimilars and new potentially superior products, may influence a decision on Libigel. Abbvie needs an ace in the hole to replace revenue if Humira starts losing sales.

In the meantime looking forward to Q3 results.

[catty]

jadite: I'm surely still here - and read every post.

[dasgrunt]

hanging in there too

what intrigues me is the unmet need for Corticotropin



Large and growing U.S. market with concentrated prescriber base
H.P. Acthar ® gel - $1 billion in annual sales with double digit script growth*
Broad label with minimal penetration
– Use focused in Neurology, Rheumatology, Nephrology and Pulmonology
– Large potential U.S. patient population ~ 4,000,000*
– Small current patient user base ~ 10,000*